How the proliferation of the urothelium is regulated is known to a little degree. E. coli lipopolysaccharide (LPS) activates the innate immune response of the urinary bladder via the Toll-like receptor 4 (TLR4) on the urothelium but induces also urothelial proliferation. We wanted to assess whether muscarinic receptors are involved in the regulation of urothelial proliferation triggered by LPS stimulation. Female Fischer 344 rats were instilled with LPS or saline (control) in the urinary bladder in the absence or presence of muscarinic receptor blockade with atropine and regeneration of the urothelium was assessed 4h and 24h later. In the Fischer 344 bladder, urothelial thinning and urothelial caspase 3 up-regulation occurred at 4h after LPS urinary bladder instillation, which were totally blocked in rats pre-treated with atropine. TLR4 was only expressed in blood vessels in the Fischer 344 bladder, while it was also expressed in umbrella cells in the Sprague-Dawley bladder. Proliferation (Ki67 incorporation) of the human urothelial cell line UROtsa was reduced in the presence of the muscarinic receptor antagonists methoctramine (M2/M4-selective) and pirenzepine (M1/M4-selective), while proliferation instead was enhanced in the presence of atropine. In UROtsa cells exposed to LPS for 24h, 4-DAMP (M3/M1/M5-selective) inhibited instead proliferation. In conclusion, muscarinic receptors regulate urothelial proliferation and LPS may induce urothelial apoptosis via muscarinic receptor-dependent pathways. Our findings also suggest that species differences exist in the expressional pattern of TLR4 in the urothelium.

Department of Oncology University of Gothenburg Gothenburg Sweden

Department of Pharmacology University of Gothenburg Gothenburg Sweden

Faculty of Medicine Charles University Hradec Králové Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc18033334

003      

CZ-PrNML

005      

20181024174519.0

007      

ta

008      

181008s2018 ne f 000 0|eng||

009      

AR

024    7_

$a 10.1016/j.intimp.2018.01.006 $2 doi

035    __

$a (PubMed)29414655

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a ne

100    1_

$a Podmolíková, L $u Department of Pharmacology, University of Gothenburg, Gothenburg, Sweden; Faculty of Medicine, Charles University, Hradec Králové, Czech Republic.

245    10

$a Cholinergic regulation of proliferation of the urothelium in response to E. coli lipopolysaccharide exposition / $c L. Podmolíková, MF. Mukanyangezi, P. Nieto-Marín, D. Giglio,

520    9_

$a How the proliferation of the urothelium is regulated is known to a little degree. E. coli lipopolysaccharide (LPS) activates the innate immune response of the urinary bladder via the Toll-like receptor 4 (TLR4) on the urothelium but induces also urothelial proliferation. We wanted to assess whether muscarinic receptors are involved in the regulation of urothelial proliferation triggered by LPS stimulation. Female Fischer 344 rats were instilled with LPS or saline (control) in the urinary bladder in the absence or presence of muscarinic receptor blockade with atropine and regeneration of the urothelium was assessed 4h and 24h later. In the Fischer 344 bladder, urothelial thinning and urothelial caspase 3 up-regulation occurred at 4h after LPS urinary bladder instillation, which were totally blocked in rats pre-treated with atropine. TLR4 was only expressed in blood vessels in the Fischer 344 bladder, while it was also expressed in umbrella cells in the Sprague-Dawley bladder. Proliferation (Ki67 incorporation) of the human urothelial cell line UROtsa was reduced in the presence of the muscarinic receptor antagonists methoctramine (M2/M4-selective) and pirenzepine (M1/M4-selective), while proliferation instead was enhanced in the presence of atropine. In UROtsa cells exposed to LPS for 24h, 4-DAMP (M3/M1/M5-selective) inhibited instead proliferation. In conclusion, muscarinic receptors regulate urothelial proliferation and LPS may induce urothelial apoptosis via muscarinic receptor-dependent pathways. Our findings also suggest that species differences exist in the expressional pattern of TLR4 in the urothelium.

650    _2

$a zvířata $7 D000818

650    _2

$a apoptóza $7 D017209

650    _2

$a atropin $x farmakologie $7 D001285

650    _2

$a kaspasa 3 $x metabolismus $7 D053148

650    _2

$a buněčné linie $7 D002460

650    _2

$a proliferace buněk $7 D049109

650    _2

$a cholinergní látky $x farmakologie $7 D018678

650    _2

$a diaminy $x farmakologie $7 D003959

650    _2

$a Escherichia coli $x imunologie $7 D004926

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a lidé $7 D006801

650    _2

$a přirozená imunita $7 D007113

650    _2

$a lipopolysacharidy $x imunologie $7 D008070

650    _2

$a pirenzepin $x farmakologie $7 D010890

650    _2

$a krysa rodu Rattus $7 D051381

650    _2

$a potkani inbrední F344 $7 D011916

650    _2

$a potkani Sprague-Dawley $7 D017207

650    _2

$a receptory muskarinové $x metabolismus $7 D011976

650    _2

$a toll-like receptor 4 $x metabolismus $7 D051197

650    _2

$a urotel $x patologie $x fyziologie $7 D019459

655    _2

$a časopisecké články $7 D016428

700    1_

$a Mukanyangezi, M F $u Department of Pharmacology, University of Gothenburg, Gothenburg, Sweden.

700    1_

$a Nieto-Marín, P $u Department of Pharmacology, University of Gothenburg, Gothenburg, Sweden.

700    1_

$a Giglio, D $u Department of Pharmacology, University of Gothenburg, Gothenburg, Sweden; Department of Oncology, University of Gothenburg, Gothenburg, Sweden. Electronic address: daniel.giglio@pharm.gu.se.

773    0_

$w MED00006034 $t International immunopharmacology $x 1878-1705 $g Roč. 56, č. - (2018), s. 222-229

856    41

$u https://pubmed.ncbi.nlm.nih.gov/29414655 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20181008 $b ABA008

991    __

$a 20181024175028 $b ABA008

999    __

$a ok $b bmc $g 1339428 $s 1030328

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2018 $b 56 $c - $d 222-229 $e 20180203 $i 1878-1705 $m International immunopharmacology $n Int Immunopharmacol $x MED00006034

LZP    __

$a Pubmed-20181008